Investment Analysts’ Weekly Ratings Changes for Vertex Pharmaceuticals (VRTX)

A number of research firms have changed their ratings and price targets for Vertex Pharmaceuticals (NASDAQ: VRTX):

• 7/13/2026 – Vertex Pharmaceuticals had its price target raised by UBS Group AG from $545.00 to $585.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Vertex Pharmaceuticals had its price target raised by Truist Financial Corporation from $542.00 to $560.00. They now have a “buy” rating on the stock.
• 7/7/2026 – Vertex Pharmaceuticals had its price target raised by Royal Bank Of Canada from $543.00 to $570.00. They now have an “outperform” rating on the stock.
• 6/30/2026 – Vertex Pharmaceuticals was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.
• 6/28/2026 – Vertex Pharmaceuticals was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/20/2026 – Vertex Pharmaceuticals was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/30/2026 – Vertex Pharmaceuticals was downgraded by Wall Street Zen from “buy” to “hold”.
• 5/27/2026 – Vertex Pharmaceuticals is now covered by Truist Financial Corporation. They set a “buy” rating and a $542.00 price target on the stock.
• 5/18/2026 – Vertex Pharmaceuticals was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.

Insider Activity

In related news, EVP Duncan Mckechnie sold 1,541 shares of the firm’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $519.00, for a total transaction of $799,779.00. Following the completion of the transaction, the executive vice president directly owned 11,001 shares of the company’s stock, valued at approximately $5,709,519. This trade represents a 12.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Joy Liu sold 1,104 shares of Vertex Pharmaceuticals stock in a transaction on Friday, May 1st. The shares were sold at an average price of $425.02, for a total transaction of $469,222.08. Following the completion of the sale, the executive vice president owned 20,729 shares in the company, valued at approximately $8,810,239.58. This represents a 5.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 18,874 shares of company stock valued at $8,707,966 in the last quarter. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.